Core A: University of Kentucky Alzheimer's Disease Core Center
核心 A:肯塔基大学阿尔茨海默病核心中心
基本信息
- 批准号:10261962
- 负责人:
- 金额:$ 35.53万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-08-01 至 2026-06-30
- 项目状态:未结题
- 来源:
- 关键词:AdministratorAlzheimer&aposs DiseaseAlzheimer&aposs Disease Core CenterAlzheimer&aposs disease related dementiaAutopsyBiologicalBrainBrain PathologyCapitalCaregiversCessation of lifeClinicalCognitiveCognitive agingCollaborationsCommunicationCommunitiesDementiaDevelopmentDoctor of PhilosophyElderlyEnsureEnvironmentEtiologyFosteringFoundationsGoalsHeterogeneityHuman ResourcesHuman VolunteersImpaired cognitionIndividualInfrastructureKentuckyKnowledgeLeadershipModalityMonitorNeurosciencesOccupational activity of managing financesPathogenicityPathologyPatientsPreventionResearchResearch ActivityResearch PersonnelResourcesRiskRisk FactorsScienceStrategic PlanningStructureSystemTissuesTraining and EducationTranslational ResearchUnited StatesUniversitiesaccurate diagnosticsbeneficiarycognitive developmentcohortcomorbiditydisease heterogeneityeffective therapyinnovationmeetingsmultidisciplinarynovel therapeuticspre-clinicalpreventprogramssuccesstraining opportunitytreatment strategyvolunteer
项目摘要
Project Summary/Abstract: Administrative Core
The ultimate goal of the UK-ADRC is to catalyze innovative and outstanding AD research while ensuring a
more rapid rate of progress toward new therapies to delay or prevent AD, so that our human volunteers,
patients and caregivers become the beneficiaries of our advances in knowledge. The Administrative Core
provides the foundation, infrastructure, leadership, overall direction, strategic planning, and integration of all
ADRC components to more rapidly achieve this goal and advance our overall theme: “Transitions from Normal
to Late-Life Multi-Etiology Dementia”. This theme builds on our traditional strengths in defining mechanisms
underlying the early changes that occur in individuals as they transition through the cognitive continuum, risk
factors associated with these cognitive states, and how mixed pathology and co-morbidities influence risk and
progression. Two historically outstanding resources of the UK-ADRC that enable research relevant to this
theme are: 1) a strong autopsy program providing clinical-neuropathological correlation and very short (2-4 hrs)
postmortem interval (PMI) research material, and 2) a unique, continuously replenished group of ~500
cognitively intact subjects followed longitudinally, together with another ~300 initially normal individuals who
transition to pre-MCI, MCI or dementia, and all committed to brain autopsy upon death. These signature
resources have contributed to our becoming one of the premier centers defining pathogenic mechanisms
underlying the transitions from normal cognitive aging to the earliest stages of cognitive impairment. The UK-
ADRC functions in a multidisciplinary, integrated, collaborative and supportive team science environment that
catalyzes high-quality AD research within the UK community, region, nation, and beyond. We will continue to
provide the infrastructure, resources and intellectual capital to enhance transdisciplinary research and scientific
interactions, develop new collaborations and partnerships, contribute to national initiatives, and offer innovative
education and training opportunities in the basic and clinical neurosciences. An effective Administrative Core is
essential for transforming our goals into accomplishments. Therefore, the Core will continue to support the
ability of our UK-ADRC to accomplish its goals, and to promote the NAPA research implementation milestones
and goals, through the following specific aims.
Aim 1: Provide leadership, administrative structure, coordination, and financial management to ensure optimal
resource utilization to meet the overall goals of the UK-ADRC.
Aim 2: Promote and catalyze clinical/translational research activities, maximize interactions with other
departments and centers, and foster new avenues of innovative research.
Aim 3: Solicit, review, select, and monitor the Developmental Projects.
Aim 4: Contribute to and interact with other ADRCs and other national collaborative activities and increase
visibility in the local and national community.
项目摘要/摘要:行政核心
英国-ADRC的最终目标是催化创新和出色的广告研究,同时确保
在新疗法方面的进步速度更快,以延迟或预防广告,以便我们的人类志愿者,
患者和看护人成为我们在知识群体进步的受益者。行政核心
提供所有人的基础,基础设施,领导力,整体指导,战略规划和整合
ADRC组件更快地实现了这一目标并提高了我们的整体主题:“从正常
到后期多性痴呆症”。这个主题以我们定义机制的传统优势为基础
在个人通过认知连续体过渡时发生的早期变化的根本变化,风险
与这些认知状态相关的因素,以及混合病理和合并症如何影响风险和
进展。英国-ADRC的两个历史上杰出的资源使研究能够与此相关
主题是:1)一个强大的尸检计划,提供临床神经病理学相关性和非常短(2-4小时)
验尸间隔(PMI)研究材料,以及2)〜500的独特,连续复制的组
认知完整的受试者纵向遵循,另一个约有300个正常人
过渡到MCI,MCI或痴呆症,并致力于死后进行大脑尸检。这些签名
资源已成为我们成为定义致病机制的首要中心之一
从正常的认知衰老到认知障碍的最早阶段的过渡基础。英国 -
ADRC在多学科,综合,协作和支持性团队科学环境中发挥作用
催化英国社区,地区,国家及以后的高质量广告研究。我们将继续
提供基础设施,资源和智力资本,以增强跨学科研究和科学
互动,建立新的合作和伙伴关系,为国家倡议做出贡献,并提供创新
基本和临床神经科学的教育和培训机会。有效的行政核心是
将我们的目标转变为成就至关重要。因此,核心将继续支持
我们的英国ADRC实现其目标并促进NAPA研究实施里程碑的能力
和目标,通过以下特定目标。
目标1:提供领导,行政结构,协调和财务管理以确保最佳
资源利用以满足英国-ADRC的整体目标。
目标2:促进和催化临床/翻译研究活动,与其他的最大相互作用
部门和中心,并培养创新研究的新途径。
目标3:征求,审查,选择和监视发展项目。
目标4:为其他ADRC和其他国家合作活动做出贡献并与之互动
地方和民族社区的可见性。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
LINDA J VAN ELDIK其他文献
LINDA J VAN ELDIK的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('LINDA J VAN ELDIK', 18)}}的其他基金
GMP Production and Extended Toxicology of an Oral Formulation Drug for Alzheimer's Disease
治疗阿尔茨海默病的口服制剂药物的 GMP 生产和扩展毒理学
- 批准号:
10624841 - 财政年份:2022
- 资助金额:
$ 35.53万 - 项目类别:
Portable and modular UDS Data Collection software to increase collaboration and engagement of Alzheimer’s Disease Research Center research software engineers
便携式模块化 UDS 数据收集软件,可增强阿尔茨海默病研究中心研究软件工程师的协作和参与
- 批准号:
10608722 - 财政年份:2021
- 资助金额:
$ 35.53万 - 项目类别:
University of Kentucky Alzheimer's Disease Research Center
肯塔基大学阿尔茨海默病研究中心
- 批准号:
10662314 - 财政年份:2021
- 资助金额:
$ 35.53万 - 项目类别:
Core G: University of Kentucky Alzheimer's Disease Core Center
核心 G:肯塔基大学阿尔茨海默病核心中心
- 批准号:
10662371 - 财政年份:2021
- 资助金额:
$ 35.53万 - 项目类别:
Core A: University of Kentucky Alzheimer's Disease Core Center
核心 A:肯塔基大学阿尔茨海默病核心中心
- 批准号:
10662339 - 财政年份:2021
- 资助金额:
$ 35.53万 - 项目类别:
Core A: University of Kentucky Alzheimer's Disease Core Center
核心 A:肯塔基大学阿尔茨海默病核心中心
- 批准号:
10459466 - 财政年份:2021
- 资助金额:
$ 35.53万 - 项目类别:
Core G: University of Kentucky Alzheimer's Disease Core Center
核心 G:肯塔基大学阿尔茨海默病核心中心
- 批准号:
10459472 - 财政年份:2021
- 资助金额:
$ 35.53万 - 项目类别:
University of Kentucky Alzheimer's Disease Research Center
肯塔基大学阿尔茨海默病研究中心
- 批准号:
10459464 - 财政年份:2021
- 资助金额:
$ 35.53万 - 项目类别:
University of Kentucky Alzheimer's Disease Research Center
肯塔基大学阿尔茨海默病研究中心
- 批准号:
10261961 - 财政年份:2021
- 资助金额:
$ 35.53万 - 项目类别:
Core G: University of Kentucky Alzheimer's Disease Core Center
核心 G:肯塔基大学阿尔茨海默病核心中心
- 批准号:
10261968 - 财政年份:2021
- 资助金额:
$ 35.53万 - 项目类别:
相似海外基金
Meeting the Challenges of COVID-19 by Expanding the Reach of Palliative Care: Proactive Advance Care Planning with Videos for the Elderly and all Patients with Dementia
通过扩大姑息治疗的范围来应对 COVID-19 的挑战:为老年人和所有痴呆症患者提供视频的主动预先护理计划
- 批准号:
10784057 - 财政年份:2023
- 资助金额:
$ 35.53万 - 项目类别:
Data Collection, Linkages, Cleaning and Sharing Core
数据采集、联动、清洗、共享核心
- 批准号:
10774555 - 财政年份:2023
- 资助金额:
$ 35.53万 - 项目类别:
The Paycheck Protection Program and its Effects on Staffing Patterns and the Outcomes of Residents Living with Dementia
薪资保护计划及其对人员配置模式和痴呆症居民结局的影响
- 批准号:
10729652 - 财政年份:2023
- 资助金额:
$ 35.53万 - 项目类别:
The Impact of Alzheimer’s Disease and Related Dementias on Nursing Home Care and Quality for Persons with Serious Mental Illness
阿尔茨海默病和相关痴呆症对严重精神疾病患者的疗养院护理和质量的影响
- 批准号:
10803736 - 财政年份:2023
- 资助金额:
$ 35.53万 - 项目类别:
"Improving Health Equity in Long-Term Care Residents with Dementia: The Role of Race and Ethnicity in Resident-to-Resident Aggression"
“改善患有痴呆症的长期护理居民的健康公平:种族和民族在居民之间的攻击行为中的作用”
- 批准号:
10644715 - 财政年份:2023
- 资助金额:
$ 35.53万 - 项目类别: